Conversely, VGLCR alone did not activate p53 (p > 0.05 vs. control), but if added before or after the glaucoma inducers it was able to counteract the adverse effects (p < 0.05 vs. NMDA+ H2O2, approximately eight times and seven times greater in both conditions, respectively). The gene discussed is TP53; the disease is glaucoma.